Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

Fast and accurate short read alignment with Burrows-Wheeler transform

Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.

Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849

Mapping and quantifying mammalian transcriptomes by RNA-Seq

Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696

Primer3—new capabilities and interfaces

Untergasser, A., Cutcutache, I., Kõressaar, T., Ye, J., Faircloth, B., Remm, M., & Rozen, S. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks596 · Cited by 9,165

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049

<tt>BLAT</tt> —The <tt>BLAST</tt> -Like Alignment Tool

Kent, W. J. (2002) · Genome Research · doi:10.1101/gr.229202 · Cited by 8,480

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887

Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response

Linares-Fernández, S., Lacroix, C., Exposito, J.-Y., & Verrier, B. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.002 · Cited by 376

Targeting cancer with mRNA–lipid nanoparticles: key considerations and future prospects

Kon, E., Ad‐El, N., Hazan‐Halevy, I., Stotsky‐Oterin, L., & Peer, D. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00811-9 · Cited by 393

Deep learning enables de novo peptide sequencing from data-independent-acquisition mass spectrometry

Tran, N. H., Qiao, R., Xin, L., Chen, X., Liu, C., Zhang, X., Shan, B., Ghodsi, A., & Li, M. (2018) · Nature Methods · doi:10.1038/s41592-018-0260-3 · Cited by 370

mRNA therapeutics in cancer immunotherapy

Beck, J. D., Reidenbach, D., Salomon, N., Sahin, U., Türeci, Ö., Vormehr, M., & Kranz, L. M. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01348-0 · Cited by 385

Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening

Orlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., Löwer, M., Vallazza, B., Beissert, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.011 · Cited by 365

Intratumoral heterogeneity and clonal evolution in liver cancer

Losic, B., Craig, A. J., Villacorta-Martín, C., Martins-Filho, S. N., Akers, N. K., Chen, X., Ahsen, M. E., von Felden, J., Labgaa, I., D’Avola, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14050-z · Cited by 371

mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection

Xu, S., Yang, K., Li, R., & Zhang, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186582 · Cited by 368

Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma

Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00455-z · Cited by 356

Progress in biopharmaceutical development

Kęsik-Brodacka, M. (2017) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1617 · Cited by 389

Alternative tumour-specific antigens

Smith, C. C., Selitsky, S. R., Chai, S., Armistead, P. M., Vincent, B. G., & Serody, J. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0162-4 · Cited by 366

Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens

Lynn, G. M., Sedlik, C., Baharom, F., Zhu, Y., Ramirez-Valdez, R. A., Coble, V. L., Tobin, K. K. S., Nichols, S. R., Itzkowitz, Y., Zaidi, N., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0390-x · Cited by 351

Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes

Chong, C., Müller, M., Pak, H., Harnett, D., Huber, F., Grün, D., Leleu, M., Auger, A., Arnaud, M., Stevenson, B. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14968-9 · Cited by 356

Three decades of messenger RNA vaccine development

Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342

Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy

Jiang, W., He, Y., He, W., Wu, G. S., Zhou, X., Sheng, Q., Zhong, W., Lu, Y., Ding, Y., Qi, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.622509 · Cited by 351

Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations

Butterfield, L. H., & Najjar, Y. G. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00973-8 · Cited by 372

Immune-mediated approaches against COVID-19

Florindo, H. F., Kleiner, R., Vaskovich‐Koubi, D., Acúrcio, R. C., Carreira, B., Yeini, E., Tiram, G., Liubomirski, Y., & Satchi‐Fainaro, R. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0732-3 · Cited by 356

Nucleic acid delivery for therapeutic applications

Gupta, A., Andresen, J. L., Manan, R. S., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113834 · Cited by 351

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer

Sethna, Z. M., Guasp, P., Reiche, C., Milighetti, M., Ceglia, N., Patterson, E., Lihm, J., Payne, G., Lyudovyk, O., Rojas, L. A., et al. (2025) · Nature · doi:10.1038/s41586-024-08508-4 · Cited by 367

Biomimetic Nanotechnology toward Personalized Vaccines

Zhou, J., Kroll, A. V., Holay, M., Fang, R. H., & Zhang, L. (2019) · Advanced Materials · doi:10.1002/adma.201901255 · Cited by 336

T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance

Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 337

Intron retention is a source of neoepitopes in cancer

Smart, A., Margolis, C. A., Pimentel, H., He, M. X., Miao, D., Adeegbe, D. O., Fugmann, T., Wong, K., & Allen, E. M. V. (2018) · Nature Biotechnology · doi:10.1038/nbt.4239 · Cited by 330

Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy

Yang, K., Halima, A., & Chan, T. A.-T. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 352

Cancer vaccines: Building a bridge over troubled waters

Sellars, M., Wu, C. J., & Fritsch, E. F. (2022) · Cell · doi:10.1016/j.cell.2022.06.035 · Cited by 332

Predicting HLA class II antigen presentation through integrated deep learning

Chen, B., Khodadoust, M. S., Olsson, N., Wagar, L. E., Fast, E., Liu, C. L., Muftuoglu, Y., Sworder, B. J., Diehn, M., Levy, R., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0280-2 · Cited by 313

Immunity, Hypoxia, and Metabolism–the Ménage à Trois of Cancer: Implications for Immunotherapy

Riera-Domingo, C., Audigé, A., Granja, S., Cheng, W.-C., Ho, P.-C., Baltazar, F., Stockmann, C., & Mazzone, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00018.2019 · Cited by 310

Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification

Bulik-Sullivan, B. K., Busby, J., Palmer, C. D., Davis, M. J., Murphy, T., Clark, A., Busby, M., Duke, F. F., Yang, A., Young, L., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4313 · Cited by 317

Re-Emergence of Dendritic Cell Vaccines for Cancer Treatment

Saxena, M., & Bhardwaj, N. (2018) · Trends in cancer · doi:10.1016/j.trecan.2017.12.007 · Cited by 307

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial

Mackensen, A., Haanen, J. B. A. G., Koenecke, C., Alsdorf, W. H., Wagner-Drouet, E., Borchmann, P., Heudobler, D., Ferstl, B., Klobuch, S., Bokemeyer, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02612-0 · Cited by 313

Recent advances in exosome-mediated nucleic acid delivery for cancer therapy

Zhang, Y., Liu, Q., Zhang, X., Huang, H., Tang, S., Chai, Y., Xu, Z., Li, M., Chen, X., Liu, J., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01472-z · Cited by 306

Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma

Smith, C. C., Beckermann, K. E., Bortone, D. S., De Cubas, A. A., Bixby, L. M., Lee, S. J., Panda, A., Ganesan, S., Bhanot, G., Wallen, E. M., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121476 · Cited by 303

Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer

Ouspenskaia, T., Law, T. E., Clauser, K. R., Klaeger, S., Sarkizova, S., Aguet, F., Li, B., Christian, E., Knisbacher, B. A., Le, P. M., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01021-3 · Cited by 333

Heterogeneity of the tumor immune microenvironment and its clinical relevance

Jia, Q., Wang, A., Yuan, Y., Zhu, B., & Long, H. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00277-y · Cited by 332

Proton-driven transformable nanovaccine for cancer immunotherapy

Gong, N., Zhang, Y., Teng, X., Wang, Y., Huo, S., Qing, G., Ni, Q., Li, X., Wang, J., Ye, X., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-00782-3 · Cited by 300

A review of glioblastoma immunotherapy

Medikonda, R. T., Dunn, G. P., Rahman, M., Fecci, P. E., & Lim, M. K. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03448-1 · Cited by 307

Nanomedicine Tumor Targeting

Lammers, T. (2024) · Advanced Materials · doi:10.1002/adma.202312169 · Cited by 311

Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics

Guo, Z. S., Lu, B., Guo, Z., Giehl, E., Feist, M., Dai, E., Liu, W., Storkus, W. J., He, Y., Liu, Z., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0495-7 · Cited by 296

Genetic and non-genetic clonal diversity in cancer evolution

Black, J. R., & McGranahan, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00336-2 · Cited by 298

Non-viral precision T cell receptor replacement for personalized cell therapy

Foy, S. P., Jacoby, K., Bota, D. A., Hunter, T., Pan, Z., Stawiski, E. W., Ma, Y., Lu, W., Peng, S., Wang, C. L., et al. (2022) · Nature · doi:10.1038/s41586-022-05531-1 · Cited by 301

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

Xu-Monette, Z. Y., Zhang, M., Li, J., & Young, K. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01597 · Cited by 297

Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes

Racle, J., Michaux, J., Rockinger, G. A., Arnaud, M., Bobisse, S., Chong, C., Guillaume, P., Coukos, G., Harari, A., Jandus, C., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0289-6 · Cited by 281

Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities

Shemesh, C. S., Hsu, J., Hosseini, I., Shen, B., Rotte, A., Twomey, P. L., Girish, S., & Wu, B. M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.038 · Cited by 292

Neoantigen: A New Breakthrough in Tumor Immunotherapy

Zhang, Z., Lu, M., Qin, Y., Gao, W., Li, T., Su, W., & Zhong, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672356 · Cited by 297

A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer

Ni, Q., Zhang, F., Liu, Y., Wang, Z., Yu, G., Liang, B., Niu, G., Su, T., Zhu, G., Lu, G., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaw6071 · Cited by 280

Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system

Lhuillier, C., Rudqvist, N.-P., Elemento, O., Formenti, S. C., & Demaria, S. (2019) · Genome Medicine · doi:10.1186/s13073-019-0653-7 · Cited by 276

KRAS: From undruggable to a druggable Cancer Target

Uprety, D., & Adjei, A. A. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102070 · Cited by 271

Antitumour dendritic cell vaccination in a priming and boosting approach

Harari, A., Graciotti, M., Bassani‐Sternberg, M., & Kandalaft, L. E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0074-8 · Cited by 276

Circular RNA vaccine in disease prevention and treatment

Niu, D., Wu, Y., & Lian, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01561-x · Cited by 281

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

Pant, S., Wainberg, Z. A., Weekes, C. D., Furqan, M., Kasi, P. M., Devoe, C. E., Leal, A. D., Chung, V., Basturk, O., VanWyk, H., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02760-3 · Cited by 267

Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy

Nam, G., Choi, Y., Kim, G. B., Kim, S., Kim, S. A., & Kim, I. (2020) · Advanced Materials · doi:10.1002/adma.202002440 · Cited by 270

Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer

Ding, Z., Li, Q., Zhang, R., Xie, L., Shu, Y., Gao, S., Wang, P., Su, X., Qin, Y., Wang, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00448-5 · Cited by 272

Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders

Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 328

Genomic Medicine–Progress, Pitfalls, and Promise

Shendure, J., Findlay, G. M., & Snyder, M. W. (2019) · Cell · doi:10.1016/j.cell.2019.02.003 · Cited by 263

Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

Yarchoan, M. M., Gane, E. J., Marron, T. U., Perales-Linares, R. F., Yan, J., Cooch, N. S., Shu, D. H., Fertig, E. J., Kagohara, L. T., Bartha, G. T., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02894-y · Cited by 284

Clinical cancer immunotherapy: Current progress and prospects

Liu, C., Yang, M., Zhang, D., Chen, M., & Zhu, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.961805 · Cited by 261

Alternative mRNA splicing in cancer immunotherapy

Frankiw, L., Baltimore, D., & Li, G. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0195-7 · Cited by 253

Trial watch: TLR3 agonists in cancer therapy

Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239

Rapid Surface Display of mRNA Antigens by Bacteria‐Derived Outer Membrane Vesicles for a Personalized Tumor Vaccine

Li, Y., Ma, X., Yue, Y., Zhang, K., Cheng, K., Feng, Q., Ma, N., Liang, J., Zhang, T., Zhang, L., et al. (2022) · Advanced Materials · doi:10.1002/adma.202109984 · Cited by 247

mRNA vaccines in disease prevention and treatment

Zhang, G., Tang, T., Chen, Y., Huang, X., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01579-1 · Cited by 273

HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy

Marcu, A., Bichmann, L., Kuchenbecker, L., Kowalewski, D. J., Freudenmann, L. K., Backert, L., Mühlenbruch, L., Szolek, A., Lübke, M., Wagner, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002071 · Cited by 250

Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results

Palmer, C. D., Rappaport, A., Davis, M. J., Hart, M. G., Scallan, C. D., Hong, S., Gitlin, L., Kraemer, L. D., Kounlavouth, S., Yang, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01937-6 · Cited by 257

Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control

Lhuillier, C., Rudqvist, N.-P., Yamazaki, T., Zhang, T., Charpentier, M., Galluzzi, L., Dephoure, N., Clement, C. C., Santambrogio, L., Zhou, X. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci138740 · Cited by 256

Mechanisms of immune activation and regulation: lessons from melanoma

Kalaora, S., Nagler, A., Wargo, J. A., & Samuels, Y. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00442-9 · Cited by 252

Defining HLA-II Ligand Processing and Binding Rules with Mass Spectrometry Enhances Cancer Epitope Prediction

Abelin, J. G., Harjanto, D., Malloy, M., Suri, P., Colson, T. R., Goulding, S. P., Creech, A. L., Serrano, L. R., Nasir, G., Nasrullah, Y., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.012 · Cited by 237

Developing neoantigen-targeted T cell–based treatments for solid tumors

Yamamoto, T. N., Kishton, R. J., & Restifo, N. P. (2019) · Nature Medicine · doi:10.1038/s41591-019-0596-y · Cited by 241

Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines

Chen, L., Qin, H., Zhao, R., Zhao, X., Lin, L., Chen, Y., Lin, Y., Li, Y., Qin, Y., Li, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc2816 · Cited by 240

Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines

Aldosari, B. N., Alfagih, I. M., & Almurshedi, A. S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020206 · Cited by 248

Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer

Awad, M. M., Govindan, R., Balogh, K. N., Spigel, D. R., Garon, E. B., Bushway, M. E., Poran, A., Sheen, J. H., Kohler, V. L., Esaulova, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.003 · Cited by 244

Preclinical and clinical development of neoantigen vaccines

Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx681 · Cited by 237

An RNA toolbox for cancer immunotherapy

Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.132 · Cited by 229

Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors

Chen, F., Zou, Z., Du, J., Su, S., Shao, J., Meng, F., Yang, J. D., Xu, Q., Ding, N., Yang, Y., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci99538 · Cited by 233

Identification of tumor antigens with immunopeptidomics

Chong, C., Coukos, G., & Bassani-Sternberg, M. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01038-8 · Cited by 232

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Papachristofilou, A., Hipp, M., Klinkhardt, U., Früh, M., Sebastian, M., Weiß, C., Pless, M., Cathomas, R. L., Hilbe, W., Pall, G., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0520-5 · Cited by 233

An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses

Wang, G., Kang, X., Chen, K. S., Jehng, T., Jones, L. E., Chen, J., Huang, X. F., & Chen, S. (2020) · Nature Communications · doi:10.1038/s41467-020-15229-5 · Cited by 232

The role of cytokines in T‐cell memory in health and disease

Raeber, M. E., Zurbuchen, Y., Impellizzieri, D., & Boyman, O. (2018) · Immunological Reviews · doi:10.1111/imr.12644 · Cited by 232

Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire

Haen, S. P., Loeffler, M. W., Rammensee, H., & Brossart, P. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0387-x · Cited by 241

Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives

Gómez-Aguado, I., Rodríguez-Castejón, J., Vicente-Pascual, M., Rodríguez‐Gascón, A., Solinís, M. Á., & del Pozo‐Rodríguez, A. (2020) · Nanomaterials · doi:10.3390/nano10020364 · Cited by 229

Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects

Wu, X., Li, T., Jiang, R., Yang, X., Guo, H., & Yang, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01899-4 · Cited by 223

Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines?

Ho, N. I., Veld, L. G. M. H. I. ‘., Raaijmakers, T. K., & Adema, G. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02874 · Cited by 226

Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses

Vermaelen, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00008 · Cited by 223

Advancing to the era of cancer immunotherapy

Wang, Y., Wang, M., Wu, H., & Xu, R. (2021) · 癌症：英文版 · doi:10.1002/cac2.12178 · Cited by 221

Stem-like exhausted and memory CD8+ T cells in cancer

Gebhardt, T., Park, S. L., & Parish, I. A. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00615-0 · Cited by 234

Formulation and Delivery Technologies for mRNA Vaccines

Zeng, C., Zhang, C., Walker, P. G., & Dong, Y. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_217 · Cited by 228

Vaccine Therapies for Cancer: Then and Now

Morse, M. A., Gwin, W. R., & Mitchell, D. A. (2021) · Targeted Oncology · doi:10.1007/s11523-020-00788-w · Cited by 227

A neoantigen vaccine generates antitumour immunity in renal cell carcinoma

Braun, D. A., Moranzoni, G., Chea, V. A., McGregor, B. A., Blass, E., Tu, C. R., Vanasse, A. P., Forman, C., Forman, J., Afeyan, A. B., et al. (2025) · Nature · doi:10.1038/s41586-024-08507-5 · Cited by 245

Best practices for bioinformatic characterization of neoantigens for clinical utility

Richters, M. M., Xia, H., Campbell, K. M., Gillanders, W. E., Griffith, O. L., & Griffith, M. (2019) · Genome Medicine · doi:10.1186/s13073-019-0666-2 · Cited by 217

Cancer immunotherapy beyond immune checkpoint inhibitors

Marin-Acevedo, J. A., Soyano, A. E., Dholaria, B., Knutson, K. L., & Lou, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0552-6 · Cited by 222

Emerging strategies for combination checkpoint modulators in cancer immunotherapy

Popović, A., Jaffee, E. M., & Zaidi, N. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120775 · Cited by 209

Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications

Shi, Y., Shi, M., Wáng, Y., & You, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02002-z · Cited by 243

Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy

Efremova, M., Finotello, F., Rieder, D., & Trajanoski, Z. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01679 · Cited by 214

Engineering patient-specific cancer immunotherapies

Scheetz, L., Park, K. S., Li, Q., Lowenstein, P. R., Castro, M. G., Schwendeman, A., & Moon, J. J. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0436-x · Cited by 208

A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer

Sebastian, M., Schröder, A., Scheel, B., Hong, H. S., Muth, A., von Boehmer, L., Zippelius, A., Mayer, F., Reck, M., Atanackovic, D., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-019-02315-x · Cited by 209

Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors

Espinosa-Carrasco, G., Chiu, E. Y., Scrivo, A., Zumbo, P., Dave, A., Betel, D., Kang, S. W., Jang, H.-J., Hellmann, M. D., Burt, B. M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.025 · Cited by 211

The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case

Blenke, E. O., Örnskov, E., Schöneich, C., Nilsson, G. Å., Volkin, D. B., Mastrobattista, E., Almarsson, Ö., & Crommelin, D. J. A. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.11.001 · Cited by 221

The Changing Landscape of Therapeutic Cancer Vaccines—Novel Platforms and Neoantigen Identification

Jou, J., Harrington, K. J., Zocca, M.-B., Ehrnrooth, E., & Cohen, E. E. W. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0245 · Cited by 208

Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells

Baharom, F., Ramirez-Valdez, R. A., Tobin, K. K. S., Yamane, H., Dutertre, C., Khalilnezhad, A., Reynoso, G. V., Coble, V. L., Lynn, G. M., Mulè, M. P., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-00810-3 · Cited by 205

Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia

van der Lee, D. I., Reijmers, R. M., Honders, M. W., Hagedoorn, R. S., de Jong, R. C. M., Kester, M. G. D., van der Steen, D. M., de Ru, A. H., Kweekel, C., Bijen, H. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci97482 · Cited by 207

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy

Zuazo, M., Arasanz, H., Fernández-Hinojal, G., García-Granda, M. J., Gato, M., Bocanegra, A., Hernández, B., Martínez, M., Teijeira, L., Morilla, I., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910293 · Cited by 207

Probiotic neoantigen delivery vectors for precision cancer immunotherapy

Redenti, A., Im, J., Redenti, B. J., Li, F., Rouanne, M., Sheng, Z., Sun, W. Y., Gurbatri, C. R., Huang, S., Komaranchath, M., et al. (2024) · Nature · doi:10.1038/s41586-024-08033-4 · Cited by 216

Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy

Huang, P., Wang, X., Liang, X., Yang, J., Zhang, C., Kong, D., & Wang, W. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.12.028 · Cited by 201

Positron Emission Tomography-Guided Photodynamic Therapy with Biodegradable Mesoporous Silica Nanoparticles for Personalized Cancer Immunotherapy

Xu, C., Nam, J., Hong, H., Xu, Y., & Moon, J. J. (2019) · ACS Nano · doi:10.1021/acsnano.9b06691 · Cited by 200

An immunogenic personal neoantigen vaccine for patients with melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936

Abstract CT022: IVAC® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

Miller, M., Loquai, C., Kloke, B., Attig, S., Bidmon, N., Bolte, S., Bukur, V., Derhovanessian, E., Diekmann, J., Filbry, A., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-ct022

Precision T-cell therapy targets tumours

Melief, C. J. M. (2017) · Nature · doi:10.1038/nature23093 · Cited by 28

Abstract PR02: A personalized neoantigen vaccine in patients with high risk melanoma

Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Fritsch, E. F., Hacohen, N., & Wu, C. J. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.imm2016-pr02

Personalized melanoma vaccines

Kelly, P. N. (2017) · Science · doi:10.1126/science.357.6353.769-b